The US FDA has invited pharmaceutical companies to explore new ways of using quality overall summaries to strengthen and expedite chemistry, manufacturing and control reviews of new and generic drugs.
What FDA and industry learn could help the International Conference on Harmonization as it considers updating the quality overall summary, a component of the Common Technical Document that ICH member...